Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452162 · ClinicalTrials.gov registry record · NA
Physiologic MR Imaging of Salivary Gland Tumors
A NA study of Salivary Gland Tumor, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04452162 is a NA study of Salivary Gland Tumor that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04452162, a NA study of Salivary Gland Tumor, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04452162
The ClinicalTrials.gov registry entry for NCT04452162 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Salivary Gland Tumor appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.
NCT04452162 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04452162 about?
NCT04452162 is a clinical study titled "Physiologic MR Imaging of Salivary Gland Tumors". The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
What is the current status of trial NCT04452162?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-08-25. Estimated completion is 2026-06.
What conditions does trial NCT04452162 study?
This clinical trial studies the following conditions: Salivary Gland Tumor.
What interventions are being tested in trial NCT04452162?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04452162?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452162 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.